Working… Menu
Trial record 1 of 6 for:    zen-3694
Previous Study | Return to List | Next Study

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04471974
Recruitment Status : Recruiting
First Posted : July 15, 2020
Last Update Posted : December 22, 2020
Zenith Epigenetics
Merck Sharp & Dohme Corp.
U.S. Army Medical Research and Development Command
Information provided by (Responsible Party):
Rahul Aggarwal, University of California, San Francisco

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2025